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Abstract Amyloid precursor protein cleavage through β- and
γ-secretases produces β-amyloid peptide, which is believed to
be responsible for death of neurons and dementia in Alz-
heimer’s disease. Levels of β- and γ-secretase are increased
in sensitive areas of the Alzheimer’s disease brain, but the
mechanism of this process is unknown. In this review, we prove
that brain ischemia generates expression and activity of bothβ-
and γ-secretases. These secretases are induced in association
with oxidative stress following brain ischemia. Data suggest
that ischemia promotes overproduction and aggregation of β-
amyloid peptide in brain, which is toxic for ischemic neuronal
cells. In our review, we demonstrated the role of brain ischemia
as amolecular link between theβ- and theγ-secretase activities
and provided a molecular explanation of the possible neuro-
pathogenesis of sporadic Alzheimer’s disease.
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Introduction
The average life span of world societies in the last century
has significantly prolonged. In the near future, a continuous
increase of aged population is expected worldwide. Aging is
an important risk factor for onset of ischemic stroke and
Alzheimer’s disease [1–3]. Alzheimer’s disease and ische-
mic brain injury are characterized by widespread functional
disturbances of the human brain including dementia [2,
4–8]. Some hypotheses suggest that aged neuronal cells
have increased susceptibility to neuronal diseases since they
are as old as the people they belong to [2, 9]. On the other
hand, many of neuronal diseases can be initiated by the
same mechanisms involved in their development and pro-
gression. These disorders could be progressed by abnormal-
ities of different proteins [3, 10, 11]. Accumulation and
aggregation of certain proteins could stimulate a toxic ac-
tivity [12], which may stop neuronal function in damaged
neurons and cause neuronal death [13]. In ischemic stroke
and Alzheimer’s disease, some aberrant proteins are strong-
ly correlated with the progression of disorder [3, 10, 11].
These proteins include different parts of amyloid precursor
protein and tau protein hyperphosphorylation in brain ische-
mia and Alzheimer’s disease [10, 14–21]. The modified
proteins and/or their products like β-amyloid peptide that
is a product of parent amyloid precursor protein proteolysis
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can aggregate. When this process starts, proteins form path-
ological aggregates like amyloid plaques and neurofibrillary
tangles [10, 11, 15, 16, 19–22]. Moreover, pathological
aggregates can be observed in intra- and extracellular space.
From medical point of view, it is important if these modified
proteins are involved in neuronal dysfunction followed by
neurons’ death found in these two seemingly different dis-
eases. In any case, investigations of the mechanism
connected with the onset and progression of neuronal dis-
eases like brain ischemia and Alzheimer’s disease are of
great interest in order to resolve etiopathology and, next, to
develop effective treatment for both diseases.
In the review, we will deal with ischemic amyloid precursor
protein metabolism by β- and γ-secretases. A possible molec-
ular link between both secretases could be related to the onset
of irreversible ischemic brain alterations [13, 23]. It is claimed
that β-amyloid peptide after ischemia as well as ischemia
independently induce oxidative stress that, in turn, increases
β- and γ-secretase activities which further enhance β-amyloid
peptide production. Molecular processes of neurons’ death are
studied using experimental ischemic brain models partially
because brain ischemia is a huge problem for aged society
and partially because ischemic models produce reliable and
reproducible data. Additionally, there are many molecular sim-
ilarities and relationships between ischemic brain disorders and
Alzheimer’s disease [13, 23–26]. Finally, in the human clinical
setting, also Alzheimer’s disease is preceded by a significant
reduction of brain blood flow [27]. Some data obtained from
experimental brain ischemia investigations may apply to neu-
ron death following ischemic brain injury. However, there
should probably be many common molecular processes be-
tween ischemic neuron loss and neuron death noted in Alz-
heimer’s disease. In this review, we demonstrated the processes
in ischemic neuron death and referred to their relation to
neuron death in a brain affected by Alzheimer’s disease.
Ischemic Oxidative Stress
Reperfusion may reverse the ischemic cascade, but at the
same time, it induces a further damage [28–32]. The period
of time following brain ischemia is mainly responsible for
induction of oxidative stress due to formation of free radi-
cals [28, 29, 31, 32] which culminate as harmful factors
during reperfusion [33]. The reactive oxygen species, which
are especially responsible for oxidative stress, include su-
peroxide radical anion and nitric oxide. Furthermore,
free radicals react with each other to form oxidant
peroxynitrite. There are also other oxidant elements
such as hydroxyl free radical and hydrogen peroxide
[34]. Free radicals can cause membrane damage, lesions
of nucleic acid, and gene damage which lead to necrotic
and/or apoptotic cell death [29, 31, 32, 35] (Fig. 1).
Amyloid Precursor Protein
In 1984, the β-amyloid peptide, the main component of the
amyloid diffuse and senile plaques in brains of patients with
Alzheimer’s disease, was successfully sequenced [36]. A
purified protein derived from the twisted β-pleated sheet
fibrils in cerebrovascular amyloidosis associated with Alz-
heimer’s disease has been isolated. β-Amyloid peptide is a
soluble, highly aggregating small polypeptide of molecular
mass 4 kDa. Moreover, Glenner and Wong [36] have
claimed that β-amyloid peptide could be derived from a
unique serum precursor. Next, in 1987, the discovery of
the parent amyloid precursor protein initiated a huge
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Fig. 1 Pathogenic sequence in ischemic neuronal death through β-
amyloid peptide overproduction and dementia development. APP am-
yloid precursor protein, βA β-amyloid peptide
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investigation of the amyloid precursor protein-derived β-
amyloid peptide [37]. There are three main isoforms of
amyloid precursor protein (695, 751, and 770) derived from
the alternative splicing of the amyloid precursor protein
gene located in chromosome 21. Amyloid precursor protein
is a type 1 integral cell surface membrane protein that
resembles a signal transduction receptor [37]. Amyloid pre-
cursor protein is synthesized in the endoplasmic reticulum,
modified in the Golgi apparatus, and finally transported to
the cell surface via the secretory pathway. Amyloid precur-
sor protein is also endocytosed from the cell surface and
metabolized in the endosomal/lysosomal pathway. Proteo-
lytic processing of amyloid precursor protein by α- or β-
secretase leads to the extracellular release of soluble α-
secretase-released N-terminal of amyloid precursor protein
and β-secretase-released N-terminal of amyloid precursor
protein, respectively. Cleavage of amyloid precursor protein
on the extracellular side of the membrane by β-secretase at
the N-terminal of β-amyloid peptide and on the intracellular
side of the membrane by γ-secretase complex at the C-
terminal of β-amyloid peptide generates β-amyloid peptide
1–42 or β-amyloid peptide 1–40 and a cytoplasmic part
called an amyloid precursor protein intracellular domain.
Two different forms of β-amyloid peptide are determined
by γ-secretase activity. β-Amyloid peptide 1–42 was found
to be the most neurotoxic form. β-Amyloid peptide is pres-
ent in the blood and cerebrospinal fluid in normal individ-
uals, which suggests that the peptide’s production is
continuous in normal life [38].
Amyloid precursor protein mRNA increased twice in
focal transient ischemic brain injury and remained high
during 7 days following the insult [39]. In the above-
mentioned ischemic injury, the Kunitz protease inhibitor-
bearing isoforms were increased, but amyloid precursor
protein 695 that lacks Kunitz protease inhibitor domain
was decreased [40]. In focal persistent ischemia, amyloid
precursor protein mRNA species that contain a Kunitz-type
protease inhibitor domain were induced in the rat cortex for
21 days following the injury with maximum on the 4th day,
but total amounts of amyloid precursor protein mRNA did
not change [41]. During 7 days after focal ischemia, amy-
loid precursor protein 751 and amyloid precursor protein
770 mRNAs were induced in the ischemic area of the brain
[42]. The study of focal brain ischemia in rats with ovar-
iectomia revealed that within 1 h, there was a significant
increase in amyloid precursor protein mRNA in ischemic
cortex [43]. Still, estrogen treatment reduced the amyloid
precursor protein mRNA overexpression in ischemic cortex
[43]. This data demonstrated that estrogen may have an
important role in reducing the overexpression of amyloid
precursor protein mRNA following transient focal brain
ischemia like in Alzheimer’s disease. Thus, these studies
prove a profound effect of estrogen on ischemic brain and
suggest that the hormone may be able to stop a vicious cycle
of ischemia and neurodegenerative processes [43].
α-Secretase
α-Secretase is cleaving amyloid precursor protein in the
center of the β-amyloid peptide, and this pathway is non-
amyloidogenic. This process increases extracellular secre-
tion of the soluble α-secretase-released N-terminal of amy-
loid precursor protein domain which stops production of β-
amyloid peptide and prevents its deposition in plaques. On
the other hand, a decrease in α-secretase function contrib-
utes to the development of amyloid plaques and Alzheimer’s
disease. Additionally, α-secretase is involved in inflamma-
tion which is supported by expression of α-secretase by
astrocytes. α-Secretase mRNA in the hippocampus was
downregulated, and the activity of α-secretase was de-
creased after chronic brain hypoperfusion [44]. α-
Secretase decrease was noted in animals after ischemic brain
injury, too [45]. That may subsequently result in an accu-
mulation of amyloid precursor protein in the ischemic brain
and then activate the amyloidogenic pathway cleaving am-
yloid precursor protein. Finally, the formation of β-amyloid
peptide in postischemia increases and impairs the memory
[44].
β-Secretase
β-Secretase was found as a type 1 transmembrane protease.
β-Secretase cleaves amyloid precursor protein at the N-
terminal position of β-amyloid peptide, and this pathway
is amyloidogenic. This protease is expressed in neuronal and
glial cells. β-Secretase level, activity, and its product are
increased in platelets in Alzheimer’s disease individuals
[46]. Huge platelets pathology was observed in the ischemic
brain, too [47]. In addition to this, changes in β-secretase
expression and activity indicate a transcriptional and/or
translational control of β-secretase expression in brain
[48]. β-Secretase and amyloid precursor proteins follow
similar trafficking routs and colocalize within endosomes,
thus providing for optimal β-secretase activity. This is fol-
lowed by a significant increase of intracellular β-amyloid
peptide as well as by functional and morphological signs of
apoptotic neuronal death [49] (Fig. 1). The amyloidogenic
processing of the amyloid precursor protein by β-secretase
is important to β-amyloid peptide plaque development in
the ischemic brain [14–16, 19, 21, 50] and Alzheimer’s
disease [10]. Current data showed that an experimental brain
ischemia generates the overexpression, production, and ac-
tivity of Alzheimer’s disease β-secretase [51–54] (Fig. 1).
Other study showed for the first time the alteration in
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mRNA expression of three amyloid precursor protein
metabolism-related genes: β-secretase (BACE1), cathepsin
B, and glutaminyl cyclase mRNA, whose expression in-
creased in the hippocampus and cortex quickly following
instant recirculation [55]. One month after, BACE1 mRNA
level dropped subsequently but was still above the control
level during the whole period of observation. Another data
have demonstrated that full-length presenilin interacts with
immature β-secretase. This observation implies that prese-
nilin regulates β-secretase activity via direct interaction and
facilitates trafficking of β-secretase to different compart-
ments of cells [56].
γ-Secretase
γ-Secretase is an intramembranous protease complex of
four essential membrane proteins called aph-1, pen-2, nicas-
trin, and presenilin. Aph-1, pen-2, and nicastrin function as
transporters of γ-secretase, and they identify protease sub-
strates. Presenilin represents in complex catalytically active
component of the γ-secretase. γ-Secretase cleaves many
type-1 membrane proteins including the Notch receptor
[57], the amyloid precursor protein [49], and low-density
lipoprotein receptor-related protein [58]. Interest in γ-
secretase comes in part from the fact that this enzymatic
complex is responsible for the cleavage of amyloid precur-
sor protein that generates the β-amyloid peptide, one of key
components of amyloid plaques in Alzheimer’s disease [10]
and in ischemic human brain injury [15, 16, 19, 21, 50].
Presenilin is implicated in different processes including
influence on calcium and glutamate homeostasis and cell
death [23]. Recent data have shown that microglial cells and
astrocytes presented overexpression of presenilin and nicas-
trin after brain injury [59]. Presenilin influences inflamma-
tory processes, probably independently from β-amyloid
peptide in ischemic brain.
The protein products of the genes on chromosomes 14
and 1 are presenilin 1 and presenilin 2, respectively. The
first study of presenilin 1 mRNA overexpression in the
gerbil ischemic hippocampus was performed by Tanimukai
et al. [60]. Postischemic selective induction of presenilin 1
gene in neurons of CA3 area and dentate gyrus was ob-
served, which might be related to the resistant areas after
ischemia. In this investigation, presenilin 1 mRNA was
induced by 3 days. These data suggest that overexpression
of presenilin 1 mRNA may be associated with some re-
sponse of ischemically injured neurons. In next research,
the expression of presenilins mRNAwas investigated in the
rat ischemic hippocampus, cortex, striatum, and cerebellum
[61]. The increased levels of presenilins mRNA exhibited
the maximal value in the hippocampus and cortex sectors of
massive plaque formation in Alzheimer’s disease brain. But
the presenilin 1 and 2 genes expression in cerebellum and
striatum displayed no significant increase, and that correlat-
ed very well with areas unaffected by Alzheimer’s disease
pathology. The overexpressions were larger on the contra-
lateral side to the focal brain ischemic injury. This signifi-
cant difference may reflect a loss of brain cells expressing
presenilins genes on the ipsilateral side. Staining of prese-
nilin was more marked in glial than in neuronal cells and in
a trace of the ischemic pyramidal cells of hippocampus [62].
Presenilin is involved in the amyloidogenic processing of
amyloid precursor protein to produce β-amyloid peptide
through the γ-secretase complex (Fig. 1). It was noted that
animals with brain ischemia treated by γ-secretase inhibi-
tors demonstrated reduced damage of brain and improved
functional recovery [57]. Recently, it has been found that
focal brain ischemia induces an increase of γ-secretase
activity in the ischemic hemisphere [58]. The understanding
of the mechanism by which γ-secretase recognizes and
cleaves different proteins is of great importance to clarify
the activity of γ-secretase and its role in ischemic brain and
Alzheimer’s disease degeneration.
Link Between β- and γ-Secretases
Current data imply a correlation between triggered oxidative
stress and increased γ-secretase cleavage of amyloid pre-
cursor protein [63, 64]. Oxidative stress can influence β-
and γ-secretase activities [23, 49, 50, 64], so we can spec-
ulate that ischemic oxidative stress is the molecular link
between γ- and β-secretases, and as a consequence, the
activities of both proteases are linked to each other (Figs. 1
and 2). It was noted before that ischemic oxidative stress
increases presenilin expression [60, 61], staining [62], and
γ-secretase activity [58] in ischemic brain. Parallel β-
amyloid peptide mediates oxidative stress [12] itself that,
in turn, increases the function of the γ- and β-secretases,
and as result, it enhances β-amyloid peptide formation
(Fig. 1). The activation of β-secretase requires γ-secretase
cleavage of amyloid precursor protein and is proportional to
the level of β-amyloid peptide produced [49] (Figs. 1 and
2). Finally, a soluble β-amyloid peptide form causes necrot-
ic and apoptotic neuronal death [49] (Fig. 1). Nevertheless,
fibrillar β-amyloid peptide form can generate β-secretase
overexpression and increase activity that results in amyloi-
dogenic cleavage of amyloid precursor protein. Ischemic
data suggest that there, probably, is a positive feedback loop
between the β-secretase and the γ-secretase processing of
amyloid precursor protein [23, 50], stimulated by the release
of the different forms of β-amyloid peptide, which finally
act as important uninvestigated signaling substances. Evi-
dence that supports the above-mentioned material from ex-
perimental, global, and focal brain ischemia which are
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followed by recirculation demonstrated strong, abnormal
brain staining to the N-terminal of amyloid precursor protein
and to the β-amyloid peptide and to the C-terminal of
amyloid precursor protein, too. There was noted not only
intracellular staining [14, 22, 65–80] but also extracellular
one [14, 71, 74, 77, 80, 81].
Another data have exhibited that full-length presenilin
interacts with immature β-secretase. This evidence suggests
that presenilin regulates β-secretase activity via direct inter-
action and facilitates trafficking of β-secretase to different
compartments of cells [56]. Such evidence provides a mo-
lecular explanation for the role of ischemic oxidative stress
in sporadic Alzheimer’s disease development (Fig. 1).
Ischemic Cell Death
Oxidative stress becomes pathological in the brain when the
formation of reactive oxygen species overwhelms the ability
of the endogenous antioxidant mechanisms to neutralize
excess of reactive oxygen species, which finally leads to
cell damage/death [12, 29, 31, 32, 35, 82]. Increased gener-
ation of reactive oxygen species results in different patho-
logical changes including cleavage of DNA and damage of
membrane lipids (Fig. 2). Additionally, reactive oxygen
species can block mitochondrial respiratory chain [34]. As
a result of the above phenomenon, oxidative stress stimu-
lates mitochondria to develop transition pore which makes
mitochondria release apoptosis-related protein following is-
chemic brain injury [34, 83, 84]. Moreover, oxidative injury
to endoplasmic reticulum may be involved in neuron death
through apoptotic machinery following brain ischemia, too
[85] (Fig. 1). Reactive oxygen species activate different
interlinked signaling pathways which can be involved in
ischemic decisions about cell survival/death such as the
stress-activated protein kinases, c-Jun N-terminal kinases,
p38 mitogen-activated protein kinases, extracellular signal-
regulated kinases, and Akt pathways [86–88]. The p38
mitogen-activated protein kinase promotes the stabilization
and enhanced translation of mRNAs encoding proinflam-
matory proteins [89]. Besides, reactive oxygen species can
activate transcription factors, especially the nuclear factor-
kappa B that regulates cell survival/death by proinflamma-
tory cytokines [33]. Oxidative injury does not occur in
isolation after ischemic brain injury but involve in the com-
plex interactions between excitotoxicity, inflammation,
overproduction of β-amyloid peptide, and apoptosis [90].
After brain ischemia, phosphorylated p38 mitogen-activated
protein kinase was noted in hippocampal neurons [87] and
microglia [91], suggesting its role in the endogenous inflam-
matory response. Furthermore, p38 mitogen-activated pro-
tein kinase inhibitors have been proved to decrease brain
injury and improve neurological recovery after brain
ischemia and reduce ischemic inducted cytokine overex-
pression [92]. On the basis of the data provided, it can be
concluded that ischemia contributes to cell death caused by
β-amyloid peptide overproduction (Fig. 1). This process is
supported by a downregulation of α-secretase and upregu-
lation of β- and γ-secretases [23, 50]. Overexpression of β-
and γ-secretases following brain ischemia is strongly asso-
ciated with an increase of stress-activated protein kinases
activities. As a result, we can observe β-amyloid peptide-
dependent massive neuronal death after ischemic brain in-
jury. This suggests that brain ischemia leads to a shift in
amyloid precursor protein processing from the α-secretase
to β- and γ-secretase pathways with β-amyloid peptide
overproduction and accumulation in extracellular space
(Fig. 1). Richness of data implicates the extracellular accu-
mulation of β-amyloid peptide in the brain as one of the
important triggers of inflammation [23]. On the other hand,
a receptor for advanced glycation end products was shown
to be overexpressed by several folds in injured microglia
and neuronal cells and endothelium [21, 93–96]. Anyway,
β-amyloid peptide activates microglia cells by binding to
the receptor for advanced glycation end products [97] and to
scavenger receptor [98]. A receptor for advanced glycation
end products binding β-amyloid peptide on neuronal cells
can kill them directly by formatting inflammatory factors or
indirectly by activating microglia cells [93, 97]. In contrast,
ischemia also induces the production of intracellular β-
amyloid peptide what was shown by immunocytochemical
investigation [14, 22, 74, 77, 80]. Oligomeric β-amyloid
peptide is toxic [12] and initiates a series of events in
ischemic brain including the hyperphosphorylation of tau
protein that results in severe neurons [11, 20], microglia
[99], and oligodendrocytes [100] pathology. In addition to
this, a recent research showed that, in the early stages of
amyloid pathology, microplaques develop rapidly and local-
ly, which could damage neighboring axons and dendrites
within a few days [101], which eventually causes retrograde
neuronal death. So far, it has been claimed that the interac-
tion between newly formed amyloid microplaques and
microglia shows that, unless further activated, microglia
clear plaques unsuccessfully. However, they may restrict
their growth leading to their steady size after initial forma-
tion [101].
Recently, there has been proposed a mechanism in which
ischemic neuronal death is the result of a cell signaling
cascade initiated by the shedding of low-density lipoprotein
receptor-related protein ectodomain [102] (Fig. 2). This is
followed by γ-secretase-mediated cleavage of low-density
lipoprotein receptor-related protein transmembrane domain
and nuclear translocation of low-density lipoprotein
receptor-related protein intracellular domain [58] (Fig. 1).
Altogether, these data indicate that regulated intramembrane
proteolysis of low-density lipoprotein receptor-related
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protein is a novel pathway for ischemic neuronal death
(Fig. 2) and a potential target for the therapy of ischemic
stroke in human clinic. Several lines of evidence support the
key role of β-amyloid peptide in the neuropathogenesis of
brain ischemia like in Alzheimer’s disease [25, 103].
Ischemia and Pathogenesis of Sporadic Alzheimer’s
Disease
Some evidence suggests that the activity of β- and γ-
secretases is upregulated in the brain after ischemia [23,
50, 53, 58]. As a result of the above phenomenon, brain
ischemia triggers generation of β-amyloid peptide from
parent overexpressed amyloid precursor protein. Probably,
oxidative stress is involved in this phenomenon since this is
a reperfusion-dependent process. Oxidative stress and β-
amyloid peptide generation are reciprocally linked to each
other because β-amyloid peptide accumulations have been
proved to stimulate oxidative stress [12, 104]. Additionally,
oxidative stress increases synthesis of β-amyloid peptide
[105]. We hypothesized that ischemic cascade, including
brain ischemia as trigger, oxidative stress, stress-activated
protein kinases, and β- and γ-secretases, increased activity,
and overproduction of β-amyloid peptide finally leads to
neuronal cell death through necrosis and apoptosis (Fig. 1).
These activities are followed by increased staining of intra-
and extracellular β-amyloid peptide [14, 74, 77, 80] and by
neuropathological signs of necrotic and apoptotic neuron
death [31, 32]. These data support the idea that ischemic
overproduction of β-amyloid peptide dependent on β- and
γ-secretase-upregulated activities triggered by ischemic
oxidative injury is implicated in sporadic Alzheimer’s dis-
ease etiology.
In this review, three implications of ischemic oxida-
tive stress to sporadic pathway of Alzheimer’s disease
development have been analyzed. First, data suggest
that ischemic oxidative stress intensifies β- and γ-
secretase activities, which result in increasing β-
amyloid peptide formation. Secondly, evidence demon-
strated that the existence of a positive feedback loop,
where increased γ-secretase activity enhances β-
secretase expression and activity, is mediated partially
by the generation of β-amyloid peptide which acts as a
signaling molecule. Thirdly, this review shows that the
activation of the positive feedback loop by β- and γ-
secretases needs the stress-activated protein kinases sig-
naling cascade which is generated in Alzheimer’s dis-
ease apoptosis. In animals, ischemia increases β-
amyloid peptide formation [14, 22, 74, 77, 80], accu-
mulation of hyperphosphorylated tau protein, and fila-
ment generation similar to the one present in human
Alzheimer’s disease brain [17, 18, 20, 106, 107]. This
implies that ischemic episodes may develop neuropath-
ological alterations similar to those seen in Alzheimer’s
disease patients [24, 103].
Conclusions
Nowadays, there is a large body of direct evidence
linking brain ischemia to Alzheimer’s disease [25,
103]. This association manifests neuropathologically by
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massive neuronal death, and dementia in ischemic brain.
It is considered that β-amyloid peptide that is the prod-
uct of β- and γ-secretases proteolysis of amyloid pre-
cursor protein could be the important factor of
progressing ischemic pathology [13] and, therefore, in-
fluencing the role of secretases involved in its forma-
tion. According to recent data, these proteases can
probably be regulated by inflammation with oxidative
stress, which is developing after brain ischemia. We
have hypothesized that the inflammatory response gen-
erated as a result of ischemia triggers the Alzheimer’s
disease changes [108]. Ischemic brain alterations have
been proved to increase β-secretase [53] activity in
parenchyma with a concomitant overexpression of amy-
loid precursor protein and, subsequently, β-amyloid pep-
tide production. It is suggested that this action should
be mediated by binding of hypoxia-inducible factor 1
alpha to the promoter area of β-secretase mRNA result-
ing in increased levels of β-secretase enzyme in paren-
chyma [109]. Additionally, current data showed that
brain damage increases the expression of presenilin 1
and nicastrin in glial cells, both elements of the γ-
secretase complex [58, 59]. Another study revealed that
tau blocks transport of amyloid precursor protein from
the neuronal cell body into axons, and dendrites of
neuronal cells cause amyloid precursor deposition in
the neuronal body [110].
Contemporary investigations demonstrated that, fol-
lowing brain ischemia, hyperphosphorylated tau protein
accumulates in cortical neuronal cells and colocalizes
with signs of apoptosis. This mechanism may be in-
volved in the pathogenesis in ischemic brain degenera-
tion (Fig. 2). The above data indicate that ischemic
neuronal apoptosis is associated with tau protein hyper-
phosphorylation [17, 20]. Wen et al. [17, 20] reported
that neurofibrillary tangle-like tauopathy development in
the brain in adult female is involved in irreversible
ischemic rat brain injury. These data provide a neuro-
pathological basis for the development of Alzheimer-
type dementia in postischemic brains [7, 18, 111].
To conclude, in this review, we have tried to give a
perspective on the wide variety of interactions between
ischemic brain factors and amyloid precursor protein
secretases. On the one hand, ischemic oxidative stress
is able to increase the levels of all amyloidogenic sec-
retases. On the other hand, some secretases, such as β-
and γ-secretases, regulate the level of β-amyloid pep-
tide. Bringing all these data together, it is clear that the
association between ischemic brain and Alzheimer’s dis-
ease as suggested by the wealth of clinical and experi-
mental results is based on a series of complex molecular
interactions that we are only just beginning to under-
stand in detail.
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